The purpose of this study is to find out whether giving chemotherapy and pembrolizumab before surgery improves outcomes for patients with this type of cancer compared to having surgery right away without treatment beforehand. Treatment given before surgery is called neoadjuvant treatment. The study will compare two groups of patients: one group will receive gemcitabine and cisplatin along with pembrolizumab before and after surgery, while the other group will have surgery first without receiving these medications beforehand. The study will look at how long patients remain free from cancer-related events, such as the cancer coming back or spreading.

During the study, patients in the treatment group will receive the medications for up to six months, which includes the time before and after surgery. The medications will be given at specific doses through infusions into a vein. Patients will be monitored throughout the study for any side effects or complications from the treatment. The study will also collect information about the quality of life of participants, how well the cancer responds to treatment, and whether certain biological markers in the blood can help predict treatment outcomes. The study will track patients over time to measure various outcomes, including survival, whether the cancer returns, and where it might spread.

The study is divided into different parts. In the first parts, called Part A, Part B, and Part C, researchers will test different doses of the drug to find out which dose is safe and works best. They will carefully watch for any side effects and see how the body processes the drug. In Part D, the study will focus specifically on people with pancreatic adenocarcinoma and will look more closely at whether the drug helps shrink tumors or stop them from growing. During the study, participants will receive the study drug and will have regular check-ups to monitor their health and see how the cancer is responding to treatment.

Throughout all parts of the study, doctors will measure how much of the drug is in the blood, watch for any unwanted effects, and check if the cancer gets better, stays the same, or gets worse. They will also test whether the body develops an immune response to the drug over time. The study will track how long any positive effects last and whether people need to stop treatment or change their dose because of side effects. All participants must have already tried standard treatments that are normally used for their type of cancer, and those treatments must not have worked well enough or must no longer be available as an option.

The purpose of this study is to examine how well this combination of trifluridine/tipiracil and nanoliposomal irinotecan works in treating patients with advanced cholangiocarcinoma or gallbladder carcinoma after their previous gemcitabine-based treatment has failed. The study will look at how long patients can go without their disease getting worse, which is measured from the time they start the study treatment until their cancer grows or spreads, or until death occurs. The study will also evaluate how long patients survive overall, how many patients experience shrinkage of their tumors, what side effects occur and how serious they are, and how the treatment affects patients’ quality of life.

During the study, patients will receive the combination treatment and will be regularly checked to see how their disease is responding. Doctors will use imaging tests to monitor the cancer and will assess any side effects that occur. The study will also use questionnaires to understand how the treatment affects patients’ daily life and well-being. Patients who have had testing to identify specific changes in their tumor may only join the study if they are not suitable for other approved targeted treatments or if they choose not to receive those treatments.

The purpose of this research is to test how safe bemarituzumab is and how well it works in treating different types of solid tumors. The study is divided into two parts. In the first part, doctors will closely monitor how patients respond to the medication and any side effects that may occur. In the second part, they will evaluate how effective the medication is at fighting the cancer.

During the study, patients will receive bemarituzumab through regular infusions. The doctors will track the progress of the treatment using different medical tests and imaging scans such as computed tomography (CT) or magnetic resonance imaging (MRI). They will monitor how the tumors respond to the treatment and keep track of any changes in the patient’s health throughout the study period.

The purpose of this research is to determine if taking ivosidenib tablets can help prevent or delay the cancer from returning after initial treatment. The medication is given in the form of film-coated tablets that are taken by mouth. Patients who participate will receive the study medication for up to 12 months after completing their standard chemotherapy treatment.

During the study, patients will need to take the medication daily and attend regular medical check-ups. The treatment involves taking ivosidenib tablets at a daily dose that will not exceed 500 milligrams. Doctors will monitor patients’ health through various medical examinations and imaging tests to check if the cancer returns and to watch for any side effects of the treatment.

The purpose of this research is to determine how well patients respond to treatment by measuring how long they remain free from cancer progression within 12 months. The treatment plan involves giving the combination of medications both before and after surgery. Before surgery, patients receive treatment through infusions. If suitable, they then undergo surgery to remove the cancer. After recovery from surgery, patients continue receiving the same combination of medications.

During the study, patients will receive regular medical examinations and imaging tests to monitor their response to treatment. The medications are given through intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The total treatment period may last up to 18 months, during which patients will be closely monitored for any side effects or complications.

The PET/CT (Positron Emission Tomography/Computed Tomography) scan being studied uses a substance called 68Ga-FAPI-46, which is a radioactive tracer that attaches to certain proteins found in cancer cells. This allows doctors to potentially see cancer that might be missed by conventional imaging techniques. The purpose of the study is to evaluate whether this imaging method can detect additional cancer spread that would change the treatment approach for patients.

Participants in this study will undergo standard diagnostic tests as well as the additional 68Ga-FAPI-46 PET/CT scan. Researchers will compare the results of standard imaging with the results after adding the new PET/CT technique to see if it leads to changes in the cancer’s staging or treatment plan. The study will separately analyze results for pancreatic cancer and bile duct cancer patients.

The purpose of the study is to find out the highest concentration of these biotherapy drugs that can be used in skin tests without causing irritation in patients who are not allergic. The study will involve skin tests, such as prick tests and intradermal tests, to check for any allergic reactions. Patients who have been treated with these biotherapies and have not shown any allergic reactions will be part of the study. The study will monitor for any immediate or delayed skin reactions after the tests.

Throughout the study, patients will be contacted to confirm if there are any delayed reactions, which might occur up to a week after the skin tests. If a reaction is suspected, a photograph or video consultation with an allergist may be used to confirm it. The study aims to ensure that the skin tests are safe and do not cause unnecessary irritation to patients undergoing biotherapy treatments.

The treatments being tested include ivosidenib, a medication taken orally in the form of a film-coated tablet, and three other medications given through an infusion into a vein: durvalumab, gemcitabine, and cisplatin. The purpose of the study is to assess the safety and tolerability of these medications when used together, as well as to determine the best dose of ivosidenib to use in combination with the other drugs. The study will also look at how well this combination of treatments works in controlling the cancer.

Participants in the study will receive these treatments and be monitored for any side effects or changes in their condition. The study will be conducted in two phases: an initial phase to evaluate safety and determine the appropriate dose, followed by an expansion phase to further assess the effectiveness of the treatment combination. The trial aims to provide valuable information on the potential benefits of using these medications together for treating cholangiocarcinoma with an IDH1 mutation.

The purpose of the study is to evaluate how well the 68Ga-FAPI-46 PET imaging works in detecting gastrointestinal cancers. Participants in the study will undergo this imaging process, which is designed to provide clear pictures of the cancerous regions. The study will compare the results of this new imaging method with previous standard imaging techniques to see if it offers better detection of cancer locations.

Throughout the study, the safety of the 68Ga-FAPI-46 PET imaging will be monitored, including any side effects that may occur. The study will also assess how the imaging results might influence treatment decisions made by doctors. This research aims to improve the understanding of how effective this imaging method is in identifying and managing gastrointestinal cancers.

The purpose of the study is to evaluate how well this treatment works in shrinking or controlling the cancer four months after starting the treatment. Participants will receive the treatment over a period of 14 days, and their response to the treatment will be monitored using imaging techniques like MRI or CT scans. The study will also look at the safety of the treatment and its impact on the quality of life of the participants.

Throughout the study, the participants’ health will be closely monitored to assess any changes in their condition and to ensure their safety. The study aims to provide valuable information on the effectiveness of this treatment approach for patients with this specific type of liver cancer.

Participants in the study will receive these medications through an infusion, which means the drugs are given directly into the bloodstream. The treatment will be administered over a period of time before the planned surgery. The study will monitor the effects of the treatment on the cancer and assess the safety of the medications. The goal is to understand if this approach can improve outcomes for patients with locally advanced cholangiocarcinoma.

The study will also collect information on how long patients live without the cancer getting worse and overall survival rates. This information will help researchers understand the potential benefits and risks of using this combination of treatments for cholangiocarcinoma. The study is expected to continue until 2025, providing valuable insights into the effectiveness of this treatment strategy.

Participants in the study will undergo a surgical procedure called a partial hepatectomy, where part of the liver is removed. After the surgery, they will receive the HAIP chemotherapy to help prevent the cancer from returning. The study will monitor participants over a period of time to see if the treatment helps in keeping the cancer from coming back. The study will also look at other factors such as overall survival, quality of life, and any side effects from the chemotherapy.

The trial aims to provide valuable information on whether this approach can improve outcomes for patients with intrahepatic cholangiocarcinoma. By focusing on the recurrence of cancer in the liver, the study hopes to find a way to enhance the effectiveness of current treatments and improve the quality of life for those affected by this disease.

The purpose of this research is to determine how safe the medication is, how it moves through the body, and how effective it is in treating these types of cancer. The study is divided into two parts. In the first part, different doses of the medication will be tested to find the most appropriate amount. In the second part, researchers will evaluate how well the medication works in treating the cancer.

During the study, participants will take CYC140 once daily for 28-day cycles. The treatment will continue as long as it remains beneficial for the patient. Throughout the study, doctors will monitor patients’ health status and how their cancer responds to the treatment. Various medical assessments will be performed to track the progress of the treatment and ensure patient safety.

The purpose of this study is to evaluate how effective pemigatinib is when given to patients who have already undergone surgery or other local treatments to remove or destroy their cancer. The study will follow patients over a period of time to see if the cancer returns and to monitor their overall health and quality of life. Participants will take pemigatinib tablets by mouth and will have regular check-ups with the study team to assess their progress and any side effects they may experience.

Throughout the study, researchers will collect information on how long patients remain free of cancer recurrence, as well as any side effects they experience. They will also look at the overall survival of patients and how the treatment affects their quality of life. This information will help determine if pemigatinib is a beneficial treatment option for patients with this specific type of liver cancer.

Participants in the study will be randomly assigned to receive either pemigatinib or the combination of gemcitabine and cisplatin. Pemigatinib is taken as a tablet by mouth, while gemcitabine and cisplatin are given as infusions, which means they are administered directly into the bloodstream through a vein. The study will last for a period of up to 12 months, during which the participants will receive their assigned treatment and be monitored regularly by the study team.

The study aims to gather information on how well the treatments work in controlling the cancer and their safety profiles. Participants will undergo various assessments, including imaging tests like MRI or CT scans, to evaluate the response of the cancer to the treatment. The study will also collect data on the quality of life of the participants and any side effects they may experience during the treatment period.

The purpose of this study is to evaluate how well this combination works in patients who have operable intrahepatic cholangiocarcinoma, meaning the cancer can be surgically removed. Participants in the study will receive the combination treatment before surgery, which is known as a neoadjuvant setting. The study will follow participants over a period to observe the effects of the treatment, including how well the cancer responds and the success of the surgery in removing the cancer.

Throughout the study, researchers will monitor various outcomes, such as the number of patients who have successful surgeries with adequate margins, which means the cancer is removed with a safe amount of surrounding tissue. They will also look at the overall survival rates and the percentage of cancer tissue that is destroyed by the treatment. This study aims to provide valuable information on the potential benefits of combining SIRT with Capecitabine for treating this type of cancer.

The purpose of this study is to assess how well these treatments work together in preventing the return of cancer after surgery. Participants in the study will receive either the combination of durvalumab and tremelimumab with capecitabine or without capecitabine. The study will monitor the participants over a period of time to see if the cancer comes back and to evaluate their overall survival and quality of life. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to gather information on the safety of the treatments and their impact on liver function, as well as to collect tissue and blood samples for future research. The study is expected to last until April 2025, with the goal of improving treatment options for patients with biliary tract cancer.

The purpose of this research is to determine how well this new imaging method works in finding and measuring cancer in the pancreas and bile ducts, and how reliable it is when used repeatedly. The study is divided into three parts: the first part looks at how the imaging substance moves through the body, the second part tests how consistent the results are when the scan is repeated, and the third part examines how accurate the method is in detecting cancer and monitoring treatment response.

During the study, participants will receive intravenous injections of the imaging substance and undergo PET/CT scans. Some participants may have multiple scans to test how well the imaging technique works over time. The maximum amount of radioactive substance used in each scan is 345 megabecquerels (a unit used to measure radioactivity), and the imaging procedure typically takes place within one day.

The purpose of the study is to compare how well patients do when they receive the combination of HAI FUDR/Dex with systemic GemOx versus when they receive only systemic GemOx. The study will involve patients who have been diagnosed with inoperable intrahepatic cholangiocarcinoma, meaning the cancer cannot be removed with surgery. Participants will be randomly assigned to one of the two treatment groups. The study will monitor the progression of the disease and assess the overall survival and response rates to the treatments.

Throughout the study, patients will receive their assigned treatments and will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on the potential benefits and risks of adding HAI FUDR/Dex to the standard chemotherapy regimen for this type of liver cancer. The results could help improve treatment options for patients with inoperable intrahepatic cholangiocarcinoma in the future.

The purpose of this study is to determine the safety and effectiveness of combining BOLD-100 with FOLFOX chemotherapy in treating these types of cancers. The study is conducted in two parts. In the first part, different dose levels of BOLD-100 will be tested to find the safest and most appropriate dose. In the second part, the selected dose will be given to more patients to further study how well the treatment works.

During the study, participants will receive BOLD-100 and FOLFOX through an intravenous line (a small tube inserted into a vein). The medications will be given according to a specific schedule determined by the healthcare team. Throughout the treatment, patients will have regular check-ups to monitor their health and how well the treatment is working.

The purpose of this study is to evaluate how effective the combination of gemcitabine and cisplatin is compared to the standard care in preventing the return of cancer after surgery. Patients participating in the study will receive either the combination of gemcitabine and cisplatin or the standard care, which could be observation alone or capecitabine, depending on the stage of their cancer. The study will monitor patients over a period to see how well the treatment works in keeping the cancer from returning and to assess the overall health and quality of life of the patients.

Participants in the study will receive treatment for a set period, and their health will be closely monitored by healthcare professionals. The study aims to provide valuable information on the best treatment options for patients who have had surgery for cholangiocarcinoma or muscle invasive gallbladder carcinoma. By comparing the new treatment with the standard care, researchers hope to find the most effective way to help patients live longer without the cancer returning.

The purpose of this research is to determine how well this combination treatment works and how safe it is for patients with liver-predominant intrahepatic cholangiocarcinoma. The study will evaluate whether tumors respond to the treatment and monitor any side effects that may occur during the therapy.

The treatment plan involves first performing radioembolization, followed by a combination of the three medications given through intravenous infusion. The medications will be administered over a period of six months. Throughout the study, patients will undergo regular medical examinations and imaging tests to monitor their response to treatment and any potential side effects.

The purpose of the study is to evaluate how effective and safe tinengotinib is for these patients. Participants will receive either tinengotinib or another treatment selected by their doctor. The study will monitor the participants over a period to see how the cancer responds to the treatment and to check for any side effects. The study will also look at how long the participants live without the cancer getting worse.

In addition to tinengotinib, the study involves other medications that may be used as part of the doctor’s choice, including folinic acid, irinotecan, fluorouracil, and oxaliplatin. These medications are given through injections or infusions. The study aims to provide more information on the best treatment options for patients with this type of cancer.

During the study, patients will undergo the [18F]F-FAPI PET-CT scan in addition to the usual imaging tests like CT (computed tomography) and MRI (magnetic resonance imaging). The study will compare the results of these imaging tests to see if the new method offers any advantages. The study will also look at how the imaging results affect the treatment plan and whether it leads to any changes in the management of the disease.

In addition to the main focus on imaging, the study will also involve the use of other medications such as GlucaGen® and Scopolamine butylbromide, which are solutions for injection. These medications are used for different purposes and will be administered as part of the study protocol. The study aims to gather information on the effectiveness and potential benefits of using the new imaging technique in combination with these treatments for patients with cholangiocarcinoma.

Participants in the study will receive the medications tucatinib and trastuzumab. Tucatinib is taken orally in the form of tablets, while trastuzumab is given through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. The study will last for a period of up to 58 weeks, during which the participants will be monitored regularly to assess the effects of the treatment on their cancer. The study will also include a group of participants who will receive a placebo, which is a substance with no active medication, to compare the results.

The trial aims to understand the antitumor activity of the combination treatment in patients who have already received other treatments for their cancer. The study will look at various outcomes, such as the rate of tumor shrinkage, the duration of response to the treatment, and overall survival rates. Additionally, the study will monitor the safety of the treatment by recording any side effects or adverse events experienced by the participants. This research is important for developing new treatment options for patients with HER2-altered solid tumors.

Participants in the study will receive durvalumab through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The chemotherapy drugs used in this study are cisplatin and gemcitabine, both of which are also given by intravenous infusion. The study will take place over a period of time, during which participants will receive these treatments and be monitored regularly by healthcare professionals.

The study aims to understand the overall survival rate of participants after 12 months, as well as other factors such as progression-free survival, safety, time to develop cholangitis (an infection of the bile duct), and quality of life. Participants will be closely observed to gather information on how well the treatment works and any side effects that may occur. This information will help researchers learn more about the potential benefits and risks of this treatment combination for people with extrahepatic cholangiocarcinoma.

The purpose of the study is to evaluate how well the combination of Durvalumab with Gemcitabine and Cisplatin works compared to the combination with a placebo in terms of overall survival, which means how long patients live after starting the treatment. The study will involve patients who have not received any prior treatment for their advanced biliary tract cancer. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein.

Throughout the study, researchers will monitor the patients’ health and response to the treatment. They will look at various factors, including how long the cancer stays under control, the response rate to the treatment, and the duration of the response. The study will also assess the quality of life of the participants, including physical function and symptoms like fatigue and appetite loss. The trial is expected to continue until March 2025, with recruitment starting in April 2024.

Participants in the study will receive the medication orally, meaning it is taken by mouth. The study will observe how patients respond to the treatment over time, including any changes in their cancer and overall health. The trial will also monitor the safety of the medication by checking for any side effects or changes in health indicators such as laboratory test results and vital signs. The study aims to gather information on how long the treatment works, how it affects the progression of the cancer, and the overall survival of the patients.

Throughout the study, the effectiveness of the treatment will be evaluated by independent experts who will review the patients’ responses. The study will also consider the patients’ quality of life during the treatment, using questionnaires designed to measure their well-being. This trial is expected to continue until 2027, providing valuable insights into the potential benefits of Futibatinib for patients with advanced cholangiocarcinoma.

The purpose of the study is to evaluate how these treatments affect the overall survival of patients. The study will involve administering these medications over a period of time and monitoring the patients’ health and response to the treatment. Some patients may receive a placebo as part of the study. The study aims to understand the effectiveness of these treatments in improving survival rates and managing the disease.

Participants in the study will receive the treatments and undergo regular health assessments to track their progress. The study will also look at various factors such as the response of the tumor to the treatment, changes in quality of life, and other health indicators. The goal is to gather information that could lead to better treatment options for patients with intrahepatic cholangiocarcinoma.

The purpose of the study is to assess how well these medications work in shrinking or controlling the cancer after patients have received a standard treatment called Y-90 SIRT therapy. Y-90 SIRT therapy is a procedure that uses tiny radioactive beads to target and treat cancer in the liver. The study will monitor the response of the cancer to the treatment, as well as the safety and any side effects experienced by the participants.

Participants in the study will receive the treatment over a period of time and will have regular follow-up visits to check on their health and the progress of the cancer. The study aims to provide valuable information on the effectiveness of combining immunotherapy with Y-90 SIRT therapy for treating advanced intrahepatic biliary tract cancer.

Participants in the study will receive the treatment over a period of 24 months. The treatment involves administering the medications through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will also include a group of participants who will receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. Throughout the study, participants will be regularly monitored to evaluate their response to the treatment and to ensure their safety.

The main goal is to see how many participants experience a reduction in their cancer size or symptoms after six months of treatment. The study will also look at how long participants live without the cancer getting worse and overall survival rates. Additionally, the safety of the treatment will be assessed by recording any side effects experienced by the participants. This trial aims to provide valuable information on the potential benefits and risks of using this combination of medications for treating HER2-positive biliary tract cancer.

The purpose of the study is to determine whether photodynamic therapy or radiofrequency ablation leads to longer survival for patients with cholangiocarcinoma. Participants in the study will receive one of these treatments, and their progress will be monitored over time. The study will look at various aspects of the patients’ health, including their overall survival, quality of life, and how long they remain out of the hospital. The study will also consider other factors like the effectiveness of stents, which are small tubes used to keep the bile ducts open, and any changes in laboratory test results.

The study is expected to continue until the end of 2027, with the aim of gathering comprehensive data on the effectiveness of these treatments. By participating in this study, researchers hope to gain valuable insights into which treatment option may offer better outcomes for patients with cholangiocarcinoma.

The purpose of the study is to evaluate the safety of ivosidenib in patients who have already received other treatments for their cancer. Participants in the trial will take ivosidenib orally, and the study will monitor their health and any side effects they may experience. The trial will also look at how the cancer responds to the treatment, including how long patients live without the cancer getting worse and their overall survival. Additionally, the study will assess the quality of life of participants using a questionnaire specifically designed for patients with cholangiocarcinoma and gallbladder cancer.

Throughout the study, various health checks will be conducted, including blood tests, heart monitoring with an ECG (electrocardiogram), and assessments of general well-being. The trial aims to provide early access to ivosidenib for patients who have limited treatment options due to the advanced stage of their cancer. The study is expected to continue until the end of 2024, allowing researchers to gather comprehensive data on the safety and effectiveness of ivosidenib in treating this challenging form of cancer.

The purpose of the study is to evaluate the safety of ivosidenib in patients who have already received other treatments for their cancer. Participants in the study will receive ivosidenib and will be monitored for any side effects or changes in their health. The study will also look at how the cancer responds to the treatment, including how long patients live without the cancer getting worse and their overall survival. Additionally, the study will assess the quality of life of participants using a questionnaire designed for patients with cholangiocarcinoma.

Throughout the study, participants will have regular check-ups, which may include blood tests, heart monitoring with an ECG (a test that records the electrical activity of the heart), and assessments of their general health and well-being. The study aims to provide early access to ivosidenib for patients who have limited treatment options and to gather important information about its effects in this group of patients.

The purpose of this study is to evaluate how well these treatments work in shrinking tumors and stopping cancer from growing, as well as to assess their safety. Participants will receive these treatments through infusions, which means the medication is given directly into the bloodstream through a vein, or in the form of capsules or tablets taken by mouth. The study will last for up to 12 months, during which participants will be closely monitored by healthcare professionals to track their response to the treatment and any side effects they may experience.

Throughout the study, researchers will collect information on how the cancer responds to the treatments, how long the response lasts, and the overall survival of participants. They will also measure the levels of the immunomodulators in the blood and check for any immune reactions to these new treatments. This information will help determine the potential benefits and risks of these new therapies for people with advanced hepatobiliary cancer.

Participants in the study will be randomly assigned to receive either the new treatment with LSTA1 or a placebo, along with their standard care. The study will be conducted over a period of up to 52 weeks, during which participants will receive their assigned treatments through intravenous infusions. The study will monitor the incidence and severity of any side effects, as well as other outcomes such as overall survival, progression-free survival, and response to the treatment.

The goal of this research is to determine if the addition of LSTA1 can improve the outcomes for patients with these types of cancers. By participating in this study, researchers hope to gather valuable information that could lead to better treatment options in the future. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the new treatment or the placebo, to ensure unbiased results.

Participants in the study will receive the treatment through an infusion, which means the medication is delivered directly into the bloodstream. The study will take place over several weeks, during which the effects of the treatment will be monitored. The goal is to see if this combination of drugs can help make the cancer more manageable and improve the chances of successful surgery. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

The study aims to achieve a high rate of successful tumor removal through surgery, known as R0/R1 resection, in more than 65% of participants. Researchers will also look at other outcomes, such as how well the cancer responds to the treatment, the safety of the treatment, and the overall quality of life of the participants during and after the study. This trial is an important step in finding more effective treatments for intrahepatic cholangiocarcinoma.